The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether SGLT‐2 inhibitors changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with sulphonylureas (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether SGLT‐2 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether GLP‐1 analogues inhibitors changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with sulphonylureas (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether GLP‐1 analogues inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether insulin analogues changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with biphasic insulin (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether insulin analogues changes any adverse events other than hypoglycaemia compared with biphasic insulin (very low certainty).
It is very uncertain whether insulin analogues changes all‐cause mortality compared with biphasic insulin (very low certainty).